| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 46, 829-838, May 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology
Thematic Review |
Department of Pathology, University of Chicago, Chicago, IL 60637
Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.R500003-JLR200
1 To whom correspondence should be addressed. e-mail: reardon{at}uchicago.edu
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
In this review, the involvement of a number of less prominent
leukocyte populations in the pathogenesis of atherosclerosis is discussed. More
specifically, the roles of natural killer cells, mast cells, neutrophils,
dendritic cells, 
T-cells, natural killer T-cells, regulatory T-cells,
and B-cells are addressed.
Abbreviations: apo,
apolipoprotein; 
-GalCer, -galactosylceramide; IL,
interleukin; LDLR–/–, low density lipoprotein
receptor-deficient; MCP-1, monocyte chemoattractant
protein-1; MHC, major histocompatibility complex; NK cell,
natural killer cell; NKT cell, natural killer T-cell; OxLDL,
oxidized low density lipoprotein; PAF, platelet-activating
factor; RAG, recombination-activating gene; TCR, T-cell
receptor; Th, T-helper; TNF, tumor necrosis
factor; Treg, regulatory T-cells
Supplementary key words innate and adaptive immunity • natural killer
cells • mast cells • neutrophils • dendritic
cells • T-cells • natural killer
T-cells • regulatory
T-cells • B-cells
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
|
CELLS OF THE INNATE IMMUNE SYSTEM |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
, thereby activating other effector cells. Cell lysis depends upon
perforin forming pores in the cell membrane of target cells, through which
granzymes (serine proteases) enter the cells and initiate cell death.
Additionally, NK cells themselves can become activated through cytokine
stimulation. Therefore, NK cells are an important component of the innate immune
system through target cell killing and cytokine production and have been thought
to play a role in the developing atherosclerotic plaque as well. Direct evidence for NK cell involvement in atherogenesis is scant, although some researchers have localized NK cells to the human atherosclerotic plaque. A detailed immunohistochemical analysis of autopsy specimens derived from the Pathobiological Determinants of Atherosclerosis in Youth Study did find CD56 staining of NK cells in the intima of early lesions, but these cells were generally low in number and scattered throughout the lesions, found more so in the shoulder regions than in the necrotic core (20). Other immunohistochemical studies examining human atherosclerotic lesions contributing to aortic and cerebral berry aneurysms have found NK cells in these plaques and have implicated NK cells in the disease process itself (21, 22). Patients with severe atherosclerotic disease have higher circulating levels of NK cells (23), although a study of elderly patients with peripheral arterial disease found lower NK cell cytotoxicity on a per cell basis along with a similar trend toward an increased number of total circulating NK cells (24).
As with human atherosclerosis, only a few studies have examined NK cells in the mouse-modeled disease. Immunostaining of atherosclerotic lesions from LDL receptor-deficient (LDLR–/–) mice maintained on a high-fat diet with a carefully titrated asialo-GM1 antibody did show positive staining in early but not late lesions (25). When LDLR–/– mice were crossed with perforin-deficient mice, no change in the extent of atherosclerosis was observed, even though NK cell cytolysis was impaired. On the other hand, when LDLR–/– mice were crossed with Lystbeige mutant mice, in which the release of proteins from the cytoplasmic granules in NK cells is defective, a significant decrease in atherosclerosis was measured, again in the face of defective NK cell cytolysis. When crossing this LDLR–/– Lystbeige model onto a RAG1-deficient background, the atherosclerotic burden actually increased, although this was accompanied by an increase in plasma total cholesterol levels as well. Puzzling as this may seem, this finding potentially implicates the Lystbeige mutation as proatherogenic in the setting of adaptive immune deficiency, via effects at the vessel wall and/or on lipid metabolism. In other studies using a mouse model of transplant-associated atherosclerosis, it was determined that NK cells were not involved in this process, based on observations using Lystbeige mutant mice as recipients (26). In interpreting these studies, it is important to note that NK cells are still present in both the Lystbeige mutant and perforin-deficient models, and despite their defects in granule-mediated target cell cytolysis, these NK cells may still be capable of producing cytokines that modulate the disease process. This notion fits well with the aforementioned study of NK cells in the elderly, in which decreased cytolysis and increased numbers of circulating NK cells correlated with atherosclerosis (24).
There are a number of
chemokines present in the atherosclerotic lesion that may directly influence NK
cells. Monocyte chemoattractant protein-1 (MCP-1) functions as a potent
chemoattractant for monocytes and T-lymphocytes (27, 28),
is found in the atherosclerotic lesion, and has been shown to be a
chemoattractant for NK cells as well (29). Fractalkine (CX3CL1) is another chemokine found in
both human and murine atherosclerotic lesions via immunohistochemistry
(30, 31). Its actions include the induction of NK cell
migration and activation, leading to increased cytotoxicity and the production of
the proatherogenic cytokine IFN- (32). Finally, interleukin-15 (IL-15) is a critical trophic
and activating cytokine required for NK cell development. The expression of this
cytokine in both human and murine atherosclerotic plaques (33) may contribute to the recruitment,
maintenance, and activation of NK cells in the atherosclerotic lesion. In short,
these cytokines and others capable of NK cell recruitment and activation are
present in the atherosclerotic lesion, and their atherogenic potential may
partially be linked to NK cell involvement.
Finally, the most direct evidence to date for NK cell involvement in atherosclerosis comes from a recent study using a transgenic model overexpressing the inhibitory Ly49A receptor under the control of the granzyme A promoter (34). In this model, any cell type expressing granzyme A (including NK cells) would also express Ly49A on its cell surface, which would prevent cell activation when the inhibitory Ly49A receptor interacts with major histocompatibility complex (MHC) class I molecules on the target cell (35). Bone marrow transplantation from these mice into lethally irradiated LDLR–/– recipients resulted in a profound decrease in atherosclerosis without any changes in plasma lipids, implying that NK cells are proatherogenic. Although intriguing, the interpretation of these results is complicated, because significant numbers of natural killer T-cells (NKT cells), CD8+ cytolytic T-lymphocytes, and other lymphocytes that have the potential to express granzyme A would also be affected in this system. Regardless, this study supports the notion that NK cells are involved in the pathogenesis of atherosclerosis, although their specific mechanistic role has yet to be determined.
Mast cells
Another component of the innate immune response that has been
implicated in the pathogenesis of atherosclerosis is the mast cell. Mast cells
are bone marrow-derived cells that reside in connective or mucosal tissues and
are involved in inflammation and hypersensitivity reactions. Upon activation,
mast cells release the contents of their large cytoplasmic granules that contain
a number of biologically active agents: vasoactive substances (histamine and
leukotrienes), proteolytic enzymes (tryptase and chymase), inflammatory cytokines
[tumor necrosis factor- (TNF-)], and growth factors
[platelet-activating factor (PAF)]. The role of mast cells in atherogenesis is
likely to be related to the release of these substances after
activation.
Mast cells can be activated in a number of ways. The primary means of degranulation occurs when antigen binds to and cross-links surface-bound IgE. In addition, components of the complement cascade known as anaphylotoxins (C3a and C5a) can activate mast cells. Notably, complement is abundant in the atherosclerotic plaque (36). Aside from these stimuli, direct neural stimulation (37) or excessive cholesterol incorporation into lipid rafts (38) may be involved in activating mast cells in the plaque as well, although the primary means of mast cell activation in the context of atherosclerosis is still unknown.
Although infrequently found in nondiseased arteries, mast cells are present in human atherosclerotic lesions throughout plaque development, especially in the rupture-prone shoulder regions (39, 40). This anatomical localization highlights their purported role in promoting plaque rupture and subsequent atherothrombotic events. The proteolytic enzymes chymase and tryptase may directly degrade matrix components of the fibrous cap, leading to an unstable plaque phenotype. In addition, these enzymes have been shown to cleave and activate pro-matrix metalloproteinases in carotid artery atherosclerosis, thereby indirectly leading to matrix degradation and plaque instability (41). Finally, heparin proteoglycans and chymase have been shown to inhibit vascular smooth muscle cell proliferation and collagen synthesis in vitro, supporting the view that mast cell activation can lead to plaque instability (42).
Mast cell-derived proteases have also been implicated in the degradation of lipoproteins, leading to aberrant lipoprotein metabolism and atherogenesis. Chymase can degrade HDL-associated apolipoproteins involved in reverse cholesterol transport, including apolipoprotein (apo) A-I, apoE, and apoA-II (43, 44). More specifically, chymase degradation of these apolipoproteins inhibits ABCA1-mediated cellular cholesterol efflux while leaving scavenger receptor class B type I-mediated and passive diffusion pathways intact (45). Furthermore, chymase can also degrade phospholipid transfer protein, thereby preventing phospholipid transfer to HDL3 particles and the subsequent formation of preß-HDL (46). Mast cell degranulation can also lead to LDL degradation, more specifically apoB-100 proteolysis (47), which in turn can become a nidus for further LDL modifications, leading to inflammation and scavenger receptor-mediated uptake. Supporting this notion is the finding that chemical inhibition of chymase suppressed lipid deposition in the aortas of diet-induced hypercholesterolemic hamsters (48).
Mast cell
degranulation upon activation releases cytokines and vasoactive substances as
well. Immunohistochemical staining of atheromatous coronary arteries shows that
plaque mast cells contain the proinflammatory and atherogenic cytokine TNF-
in preformed secretory granules (49). Activated mast cells can regulate T-cell and
macrophage responses by secreting a number of other cytokines and inflammatory
agents, including MCP-1, the macrophage inflammatory proteins MIP-1 and
MIP-1ß, and various ILs (IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, and
IL-16) (50). Histamine release
from activated plaque mast cells constricts muscular arteries, which may account
for coronary vasospasms that lead to angina or subsequent myocardial infarction
(51, 52). Histamine increases endothelial permeability in part
by inducing the phosphorylation of vascular endothelial cadherin found on
vascular endothelial cells (53),
which in turn may facilitate the extravasation of lipoproteins and inflammatory
cells to atherosclerosis-susceptible regions of the vasculature. On a cellular
level, histamine can induce proliferation and matrix metalloproteinease-1
secretion by smooth muscle cells, enhance the expression of adhesion molecules by
stimulated endothelial cells, and regulate the Th1/Th2 polarization of
T-lymphocytes in the plaque (54).
Growth factors such as basic fibroblast growth factor are produced by plaque mast
cells and may promote plaque progression and neovascularization (55). Expression of 5-lipoxygenase by plaque
mast cells may not only contribute to the production of the inflammatory
leukotrienes but also may lead to the oxidation of retained lipids, further
driving atherogenesis (56).
Finally, mast cells appear to be associated with the process of vascular
calcification seen in advanced plaques (40). Therefore, there is increasing evidence that mast
cells are not only present in the atherosclerotic plaque but also may help drive
the inflammatory response that characterizes this
disease.
Neutrophils
The neutrophil is the most common
type of leukocyte found in the circulation and is a major component of the innate
immune response. These short-lived phagocytic cells are involved primarily in
acute inflammation by engulfing damaged tissue and bacteria, killing invading
microbes through the respiratory burst, and secreting proteolytic enzymes such as
neutrophil elastase and matrix metalloproteinases. A number of epidemiological
and clinical studies have found leukocytosis in general and specifically
increased levels of neutrophils in the circulation to be an independent risk
factor for coronary heart disease (57). Although neutrophils generally are not detected in
stable atherosclerotic plaques, they are prevalent in eroded or ruptured plaques
obtained from patients with acute coronary syndromes (58). At this time, it is unclear whether the proteinases
secreted by recruited neutrophil lead to plaque erosion and rupture or whether
these cells just accumulate at the site of tissue damage, especially given that
these matrix-degrading enzymes are also synthesized by other cell types in the
plaque, namely macrophages and smooth muscle cells (59–61) and possibly mast cells as well. Activated neutrophils
also secrete myeloperoxidases, which may contribute to atherosclerosis by
oxidizing LDL, leading to uptake by macrophages (62) as well as by modifying apoA-I and thereby attenuating
ABCA1-dependent cholesterol efflux (63).
|
CELLS THAT BRIDGE THE INNATE AND ADAPTIVE IMMUNE RESPONSES |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
Dendritic cells initially described by Steinman and Cohn (64) are professional antigen-presenting
cells that are able to initiate primary immune responses. Although dendritic
cells as a family are heterogeneous and functionally diverse, these bone
marrow-derived cells arise from a common CD34+ progenitor and progress
functionally through different stages of development. Dendritic cells are able to
regulate the immune response to foreign and self-antigens and therefore are
important in either initiating an adaptive immune response or inducing tolerance
(65). To generalize dendritic
cell maturation, immature dendritic cells efficiently sample their antigenic
microenvironment through macropinocytosis and receptor-mediated endocytosis.
Activating signals transmitted largely by the diverse complement of Toll-like
receptors expressed by dendritic cells induce maturation (66). This functional change is characterized
by a downregulation of the endocytic machinery and an upregulation of the
expression of antigen-presentation molecules (MHC I and II, CD1), costimulatory
molecules (CD40, CD80/B7.1, CD86/B7.2), and the secretion of inflammatory
cytokines (such as IL-12 and TNF-) (66). This phenotypic switch facilitates the interaction
with and subsequent activation of T-lymphocytes, initiating the adaptive immune
response (67).
Dendritic cells are a component of the proposed vessel-associated lymphoid tissue and are found in the intima of susceptible arteries before atherosclerotic lesion development (68). Monocyte precursors of macrophages and dendritic cells are also recruited to the growing plaque by the activated endothelium throughout atherogenesis (69). Dendritic cells have been identified in the atherosclerotic plaques of both humans and mice by immunohistochemical and PCR-based approaches, implicating them in the pathogenesis of the disease (70–72). Dendritic cells colocalize with T-lymphocytes in the shoulder regions of rupture-prone atherosclerotic plaques (73), suggesting that antigen presentation and costimulation by plaque dendritic cells lead to the activation of T-lymphocytes at this site, which may ultimately contribute to plaque destabilization and subsequent atherothrombosis. Dendritic cells in the vessel wall also express components of the complement system, namely C1q, which likely facilitate the capture of immune complexes in the atheroma (74).
Modified lipids present in
atherosclerosis have been shown to influence dendritic cell maturation and
activation in vitro. Oxidized low density lipoprotein (OxLDL) not only promotes
monocyte to dendritic cell maturation (75) but also increases the expression of
antigen-presenting and costimulatory molecules on the mature dendritic cell
(76). One of the modified lipids
generated during the oxidative process is lysophosphatidylcholine, which may
induce dendritic cell maturation directly through G-protein-coupled receptor
signaling (77) or indirectly by
preventing the maturation block mediated by peroxisome proliferator-activated
receptor signaling (78).
The liberation of signaling phospholipids by secretory phospholipase
A2 has also been implicated in dendritic cell maturation (79). On the other hand, the maturation and
antigen-presentation ability of dendritic cells can be inhibited by statins
(80), the cholesterol-lowering
class of drugs that has been found to have a number of immunomodulatory effects
as well. Dendritic cells treated with polyunsaturated fatty acids of the n-3 and
n-6 family also display a maturation block when challenged with
lipopolysaccharide, suggesting that part of the reported anti-inflammatory and
atheroprotective effect of these dietary fatty acids (81, 82)
may be linked to preventing dendritic cell activation (83). Finally, recent studies have identified other lipid
mediators that may be responsible for retaining dendritic cells in the
atherosclerotic plaque, namely PAF and 18:1 lysophosphatidic acid (84, 85). By preventing dendritic cells from leaving the
plaque, these lipid mediators contribute to both continued plaque growth and the
lesional localization of the inflammatory response to plaque antigens.
Interestingly, HDL-associated PAF acetylhydrolase can inhibit this dendritic cell
retention (85), highlighting
another atheroprotective attribute of HDL.
Other recognized risk factors for atherosclerosis may also directly influence dendritic cell biology in the plaque. Nicotine as a major component of cigarette smoke is able to dose-dependently activate dendritic cells, leading to increased Th1 cytokine secretion by T-cells (86). On the other hand, the nonenzymatic glycation of proteins that occur in the setting of diabetes appears to promote dendritic cell maturation but prevents their expression of costimulatory molecules and their ability to activate T-cells (87). Finally, dendritic cells may play an important role in the inflammation induced by infectious agents in the vessel wall, another potential contributor to atherogenesis (65, 88).
T-lymphocytes
T-cells are members of the adaptive immune response that
respond to specific antigens that complement their rearranged T-cell receptor
(TCR). Although the majority of T-lymphocytes express the ß TCR, another
subset of T-cells exist that bear the type of TCR. These cells
represent less than 5% of the T-cell population in the peripheral human blood,
although they are enriched in specific tissues, including the gastrointestinal
mucosa, skin, and splenic pulp, as well as at sites of chronic inflammation, such
as the joint synovium in rheumatoid arthritis (89). T-cells have limited TCR diversity, are
thought to be important for the initial defense against epidermal and mucosal
pathogens, and can either activate or suppress other lymphocyte subsets
(90). This immunomodulatory
function stems largely from the cytokines they produce, which include both Th1
and Th2 types, namely IL-2, IL-4, IL-5, IL-10, and IFN- (91). In contrast with traditional ß
T-cells, some T-cells do not require antigen processing and
presentation in the context of MHC molecules to respond to their cognate antigens
(91). This unique property of
T-cells to rapidly respond to free antigen positions these cells as
bridging lymphocytes between the innate and adaptive immune responses.
T-cells have been detected in the intima of human atherosclerotic lesions,
especially in the early stages of lesion formation (20, 92).
In the lesions of LDLR–/– and
apoE–/– mice, transcripts for the -TCR chain have
been identified using laser-capture microdissection with subsequent RNA isolation
and RT-PCR analysis (P. A. VanderLaan, C. A. Reardon, and G. S. Getz, unpublished
data). The role of T-cells in atherosclerosis remains unclear, but
overall these cells may be proatherogenic, because the absence of
T-cells led to a 15% reduction in plasma total cholesterol levels and a 21%
reduction in aortic sinus atherosclerosis in 18 week old
apoE–/–/TCR–/– mice, although
these differences did not achieve statistical significance (93).
NKT lymphocytes
It is becoming very clear that the chronic inflammation of
atherosclerosis encompasses components of both innate and adaptive immunity
(15). To understand this
interconnection, one cell type in particular warrants further investigation: the
NKT lymphocyte. NKT cells are a subset of lymphocytes characterized by the
coexpression of both NK cell markers (NK1.1/CD161) and a functional TCR complex.
The most intriguing property of NKT cells from the standpoint of atherosclerosis
researchers is their ability to recognize lipid and glycolipid antigens presented
on CD1d molecules by their semi-invariant TCR (predominantly
V14J18/Vß8 for mice and V24J18/Vß11 for humans). CD1
molecules are a family of nonpolymorphic cell surface glycoproteins expressed by
certain antigen-presenting cells and have structural and functional similarities
to MHC proteins (94). Although a
number of bacterial glycolipids, such as phosphoinositol mannosides,
lipoarabinomannan, mycolic acids, and hexosyl-1-phosphoisoprenoids, have been
found to be presented by CD1 molecules, endogenous antigens for CD1d remain
largely unknown (95), although
recently Bendelac and colleagues (96) identified the lysosomal glycosphingolipid
isoglobotrihexosylceramide as a potential endogenous ligand for both human and
murine NKT cells. Experimentally, this lack of activating endogenous antigens has
been bypassed by using the synthetic ligand -galactosylceramide
(-GalCer) derived from marine sponges to study NKT cell physiology.
-GalCer specifically and robustly activates NKT cells in a CD1d-dependent
manner when processed and presented by antigen-presenting cells (97).
Because NKT cells share many characteristics of both NK cells (innate immunity) and T-cells (adaptive immunity), this lymphocyte in particular is positioned as an immunomodulator by bridging the gap between these distinct phases of the early and late immune response. The cross-talk between NKT cells and other lymphocytes has been described previously. In mice, specific activation of NKT cells resulted in concomitant cytokine production by NK cells and the expression of the activation marker CD69 by NK cells, B-lymphocytes, and CD8+ T-lymphocytes in vivo (98). Furthermore, NKT cells have also been shown to directly promote B-lymphocyte proliferation and antibody production in vitro (99, 100). In all cases, these effects were found to be CD1d-dependent, highlighting the importance of the CD1d-TCR interaction in NKT cell activation.
Because one of the earliest events in the pathogenesis of atherosclerosis is the retention and subsequent oxidative modification of lipids and lipoproteins in the vessel wall, it follows that the NKT cell may be involved in reacting to these lipid neoantigens in the plaque when presented on CD1 molecules by either macrophages or dendritic cells. In fact, glycosphingolipids and gangliosides have been identified in human atherosclerotic tissue, and increases in plasma cholesterol levels are associated with increased glycosphingolipids as well (101–103). In apoE–/– mice, multiple gangliosides have been extracted from the diseased vessel wall, and plasma levels of gangliosides were increased by 7-fold compared with those of wild-type controls (101). Therefore, it is attractive to hypothesize that NKT cells may be activated by modified lipid antigens either present in or induced by oxidized lipoproteins.
Direct
evidence for NKT cell involvement in atherosclerosis is limited to a handful of
studies. In human atherosclerotic lesions, macrophage foam cells have been shown
to strongly express all four human CD1 proteins (CD1a, -b, -c, and -d)
(104). In patients with both
stable and unstable angina, a decrease in the number of circulating NKT cells was
observed. One possible explanation for this finding is that once the NKT cells
are activated, they secrete IFN- and subsequently undergo apoptosis, thus
accounting for the decreased numbers of these cells in the circulation
(105). On the other hand, it was
recently reported that activation of NKT cells does not necessarily lead to
apoptosis but instead can result in a downregulation of the TCR and NK1.1/CD161
to prevent overstimulation (106). In the lesions of LDLR–/– and
apoE–/– mice, transcripts for the semi-invariant TCR
(V14J18) have been identified using laser-capture microdissection with
subsequent RNA isolation and RT-PCR analysis (P. A. VanderLaan, C. A. Reardon,
and G. S. Getz, unpublished data). In apoE–/– mice,
exogenous administration of lipopolysaccharide increased both the extent of
atherosclerotic lesions and the numbers of circulating and plaque NKT cells
(107). Exogenous administration
of -GalCer increased atherosclerosis in apoE–/– mice,
whereas CD1d-deficient mice showed reduced atherosclerotic lesion development
(108–110). This -GalCer-driven increase in
atherosclerosis was accompanied by a dramatic release of both the atherogenic
cytokine IFN- as well as IL-4 by NKT cells (110). Interestingly, it has been shown that a gender
dimorphism exists with respect to -GalCer-induced cytokine secretion, with
significantly higher levels of IFN- achieved in the serum of females versus
males, whereas there was no difference in IL-4 levels (111). In vitro experiments have shown that macrophages
incubated with oxidized LDL display increased expression of CD1d, which in turn
can induce NKT cells to produce IFN- (109). Finally, a recent study not only suggested that NKT
cell involvement in atherogenesis is mostly limited to the early fatty streak
lesions with little effect on larger and more advanced lesions but also found
that the absence of NKT cells did not significantly alter cytokine mRNA levels in
the vessel wall (112). An
important point here is that all the aforementioned experiments were performed in
the presence of an otherwise functional immune system; therefore, the
proatherogenic potential of NKT cells may be attributable to their interactions
with other lymphocytes present either in the plaque itself or in other lymphoid
compartments. In any case, at this time it appears that CD1d-mediated activation
of NKT cells results either directly or indirectly in an inflammatory cytokine
expression profile that drives the progression of atherosclerotic lesion
development.
|
CELLS OF THE ADAPTIVE IMMUNE SYSTEM |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
and the Th2 cytokines IL-4 and IL-5 by T-cells isolated from the
adoptively transferred mice. Regardless, the ability of these cells to modulate
the immune response makes them attractive therapeutic targets in preventing
atherosclerosis.
B-lymphocytes
Experimentally, B-cells
as a group have been shown to be atheroprotective, because eliminating them
either genetically (9) or through
splenectomy (10) increases
atherosclerosis. Although B-lymphocytes generally are not detected in
atherosclerotic lesions (115,
116), an adventitial
localization of these cells may partially explain their demonstrated influence on
plaque development (117,
118). On the other hand, the
major immunological product of B-cells, immunoglobulins, is readily identified in
the plaque throughout lesion development (119, 120). Antibodies that recognize OxLDL have been found in
the circulation of both humans and mice (121, 122). This has focused attention on the role that a
subpopulation of innate B-cells namely B-1 B-lymphocytes, may play in
atherogenesis, which will be covered extensively by Witztum and colleagues in a
separate review in this series. In total, most studies to date suggest that
B-lymphocytes in general are antiatherogenic on the basis of the protective
antibodies they produce, but it is important to consider other roles that B-cells
may play in modulating the atherosclerotic immune response, namely through
antigen presentation and cytokine secretion.
B-cells are able to selectively internalize their cognate antigen via the B-cell receptor, which makes B-cells extremely efficient at presenting their respective antigens to T-cells. B-cells also express costimulatory molecules, enabling them to activate T-cells that also recognize the same antigen, thereby initiating and amplifying the immune response (123). For this reason, B-cells should be considered along with the other antigen-presenting cells involved in atherosclerosis, macrophages and dendritic cells. B-cells isolated from the spleens of aged apoE–/– mice with substantial atherosclerotic lesions had significantly increased expression of the costimulatory molecules CD80/B7.1 and CD86/B7.2 compared with B-cells from either younger apoE–/– mice devoid of atherosclerosis or age-matched C57BL/6 controls (124). Furthermore, increased numbers of circulating activated B-cells expressing CD80 positively correlate with the severity of carotid atherosclerosis as assessed by intima-media thickness using high-resolution ultrasonography (125). Finally, certain subsets of B-cells are characterized by increased CD1d expression (126), which implies that certain B-cells could potentially present lipid antigens to NKT cells, although this intriguing link to atherogenesis has not been demonstrated.
In addition to their ability to
produce antibodies and present antigens to T-cells, it was recently demonstrated
that B-cells can regulate the immune response directly through cytokine secretion
as well. Under certain conditions, B-cells are able to produce a variety of
cytokines once thought to be restricted to T-cells, including IL-1, IL-2, IL-4,
IL-6, IL-10, IL-12, IL-13, IL-16, IFN-, lymphotoxin- and -ß,
transforming growth factor-ß, and TNF- (124). The particular cytokines produced by any given
B-cell appear to be context-dependent, influenced by both the local cytokine
milieu and any stimulatory signals (such as through the B-cell receptor or CD40)
(127). Distinct subsets of
cytokine-secreting B-cells have been identified recently. Effector B-cells (Be1
and Be2) secrete either type 1 cytokines (IFN-, IL-12, and
lymphotoxin-) or type 2 cytokines (IL-2, IL-4, and IL-6) respectively
(123, 128), analogous to the Th1 versus Th2 polarization
paradigm of T-lymphocytes. Regulatory B-cells are similar to Treg in
that they primarily produce the antiatherogenic cytokine IL-10, which can
suppress inflammation and inhibit the Th1-biased response (123). Interestingly, B-1 cells are a major
source of B-cell-derived IL-10 (129), which may implicate this subset of B-cells in
helping to suppress the inflammatory response to OxLDL in atherogenesis. Although
intriguing and potentially important in the pathogenesis of atherosclerosis,
there is currently a paucity of studies that examine the specific role of
cytokine production by B-cells in this disease
process.
|
CONCLUSIONS |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
|
ACKNOWLEDGMENTS |
|---|
Manuscript received February 7, 2005 and in revised form March 8, 2005.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONCELLS OF THE INNATE...CELLS THAT BRIDGE THE...CELLS OF THE ADAPTIVE...CONCLUSIONSREFERENCES |
|---|
